SS Innovations International (NASDAQ: SSII) reported record second-quarter 2026 revenue of $13.9 million, a 39.4% increase from $10.0 million in the same period last year, signaling continued momentum for its SSi Mantra surgical robotic platform. The company’s first-half revenue reached $25.0 million, up 65.6% from $15.1 million in the prior-year period, according to a press release issued by the company.
The revenue growth was driven by a 30.4% increase in SSi Mantra system installations during the quarter, bringing the total installed base to 224 systems across 12 countries. Cumulative surgeries performed using the platform reached 12,272, underscoring its clinical utility and adoption. Gross profit for the second quarter rose 20.0% to $7.1 million, though gross margin contracted to 50.9% from 59.1% in the year-ago quarter, reflecting investments in scaling operations. For the first half, gross profit increased 77.5% to $12.4 million, with gross margin improving to 49.6% from 47.4%.
The company highlighted upcoming regulatory milestones as potential catalysts: it is targeting FDA clearance by the first quarter of 2027 and EU CE marking by the end of 2026. These approvals would open access to two of the world’s largest medical device markets, potentially accelerating adoption of the SSi Mantra system. Additionally, SS Innovations has been advancing its telesurgery capabilities, which extend the platform’s clinical profile and could differentiate it in a competitive landscape.
While system installations remain the primary commercial growth driver, the company’s telesurgery achievements are positioning SSi Mantra as a versatile tool for remote and minimally invasive procedures. The growing installed base and cumulative surgery count provide evidence of clinical acceptance, which is critical for converting regulatory clearances into sustained revenue growth.
The company’s financial performance comes amid a broader trend of increasing adoption of robotic-assisted surgery, as hospitals seek to improve patient outcomes and operational efficiency. With a significant backlog of installations and a clear regulatory pathway, SS Innovations appears well-positioned to capitalize on this demand. However, investors should consider the risks outlined in the company’s filings, including those detailed under “Risk Factors” in its most recent Annual Report on Form 10-K and subsequent quarterly reports (https://nnw.fm/zxrT1).
The company’s forward-looking statements involve uncertainties that could cause actual results to differ materially from expectations. As SS Innovations continues to expand its global footprint and pursue regulatory approvals, its ability to manage costs and scale production will be key to sustaining profitability. The company’s newsroom provides updates on its latest developments (https://ibn.fm/SSII).
